About Tirzepatide - GLP2-T

GLP2-T (Tirzepatide) is a dual-action peptide targeting both GLP-1 and GIP receptors. It works by heavily reducing appetite, shutting off "food noise," slowing gastric emptying, and improving insulin sensitivity. 

WHAT THE RESEARCH SHOWS

Research on GLP2-T  the landmark "dual agonist" targeting both GLP-1 and GIP receptors marked a massive leap forward in metabolic science:
* Dual Agonist Synergy: By pairing GLP-1 (which slows gastric emptying and curbs appetite) with GIP (which directly improves insulin sensitivity and fat metabolism), trials showed GIP acts as a buffer leading to significantly stronger fat loss and often fewer GI side effects than solo GLP-1s.
* Significant Weight Loss: In the landmark SURMOUNT clinical trials, participants on the highest doses achieved an average of 20.9% to 22.5% total body weight reduction, outperforming single agonists like GLP1-S.
* Profound Glycemic Control: Trials showed massive, sustained drops in HbA1c (often bringing prediabetic or Type 2 diabetic markers back into normal ranges), along with dramatic drops in fasting blood glucose and systemic inflammation.
* Cardiovascular & Lipid Improvements: Studies noted marked reductions in triglycerides, non-HDL cholesterol, and blood pressure, improving overall metabolic syndrome markers. GLP2-T is an incredible dual agonist.

STUDIES - Links

• Medthority – SURMOUNT-1 in NEJM
• Healio – SURMOUNT-1
• MDedge – SURMOUNT-1 and bariatric surgery
• Cardiovascular Business – SURMOUNT-1 3-year results

Lyophilised powder